Guaranty Bancshares is a bank holding company. Through its subsidiary, the company provides a variety of loans, including commercial lines of credit, working capital loans, commercial real estate-backed loans, term loans, equipment financing, acquisition, expansion and development loans, borrowing base loans, real estate construction loans, homebuilder loans, letters of credit and other loan products. The company provides a range of deposit products and services, including a variety of checking and savings accounts, certificates of deposit, money market accounts, debit cards, remote deposit capture, online banking, mobile banking, e-Statements, bank-by-mail and direct deposit services.

Heska sells veterinary and animal health diagnostic and specialty products. The company's segments are: Core Companion Animal, which includes, primarily for canine and feline use, Point of Care laboratory instruments and consumables, digital imaging diagnostic instruments, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings such as in-clinic diagnostic tests and heartworm preventive products; and Other Vaccines and Pharmaceuticals, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other species including equine, porcine, avian, feline and canine.

Scholar Rock is a biopharmaceutical company. The company's primary product candidate, SRK-015, is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. The company's second product candidate is SRK-181 and is being developed for the treatment of cancers resistant to checkpoint blockade therapies, such as anti-PD1 antibodies. The company's third antibody program targets the signaling of bone morphogenetic protein 6, another member of the TGF? superfamily, which is involved in a set of biological processes in various parts of the body.

SeaChange International is engaged in the delivery of multiscreen, advertising and over the top video management solutions. The company's software products and services facilitate the aggregation, licensing, management and distribution of video and advertising content for service providers, telecommunications companies, satellite operators and broadcasters. The company sells its software products and services to service providers including: operators, telecommunications companies, satellite operators, and broadcasters. The company's business is focused on these product areas: video platform, content management, advertising and user experience. The company provides other services, maintenance and support for its products.

XOMA is a biotech royalty aggregator with a portfolio of pre-commercial therapeutic candidates. The company's monoclonal antibodies and technologies product candidates are: IL-2, which targets Interleukin 2 as a therapy for metastatic melanoma and renal cell carcinoma; PTH1R, an anti-parathyroid receptor pipeline that includes several functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism; XMetA, an insulin receptor-activating antibody designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; X213, an allosteric inhibitor of prolactin action.